Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Heart Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Heart Valve Disease Global Clinical Trials Review, H2, 2017

Heart Valve Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Valve Disease Global Clinical Trials Review, H2, 2017" provides an overview of Heart Valve Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Valve Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017" provides an overview of Helicobacter pylori Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Helicobacter pylori Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Helminthiasis Global Clinical Trials Review, H2, 2017

Helminthiasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthiasis Global Clinical Trials Review, H2, 2017" provides an overview of Helminthiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Helminthic Infestations Global Clinical Trials Review, H2, 2017

Helminthic Infestations Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthic Infestations Global Clinical Trials Review, H2, 2017" provides an overview of Helminthic Infestations clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthic Infestations. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Hemangiomas Global Clinical Trials Review, H2, 2017

Hemangiomas Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H2, 2017" provides an overview of Hemangiomas clinical trials scenario. This report provides top line data relating to the clinical trials on Hemangiomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hematological Tumor Global Clinical Trials Review, H2, 2017

Hematological Tumor Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematological Tumor Global Clinical Trials Review, H2, 2017" provides an overview of Hematological Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Hematological Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Hematoma Global Clinical Trials Review, H2, 2017

Hematoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematoma Global Clinical Trials Review, H2, 2017" provides an overview of Hematoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hematoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500